Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT01587651

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01587651
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01587651. Randomized; no masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-04-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
Acronym
SWAP-2
Intervention (Drug)
Prasugrel Loading Dose
Intervention (Drug)
Prasugrel Maintenance Dose
Intervention (Drug)
Ticagrelor Maintenance Dose
Lead sponsor
Daiichi Sankyo (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01587651
Content hash
faf85fb1f2e319c6a124ca57c5ad5fa240f05201e05cd4ae4cbc3a6c9afc3ed8